{
  "slug": "abbvie-inc",
  "symbol": "ABBV",
  "name": "AbbVie Inc",
  "fiscalYearEnd": "2025-12-31",
  "filing": {
    "accession": "0001551152-26-000008",
    "form": "10-K",
    "filed": "2026-02-20",
    "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm"
  },
  "model": "claude-haiku-5-5",
  "promptVersion": "2026-10-31.2",
  "generatedAt": "2026-10-31T19:47:22.870591+00:00",
  "segments": null,
  "sections": {
    "businessModel": [
      {
        "de": "Skyrizi (Risankizumab) ist ein Wirkstoff, der Interleukin-23 (IL-23) blockiert.",
        "en": "Skyrizi (risankizumab) is a drug that blocks interleukin-23 (IL-23).",
        "quote": "Skyrizi (risankizumab) is an interleukin-23 (IL-23) inhibitor"
      },
      {
        "de": "Ubrelvy ist ein Wirkstoff, der Rezeptoren des Calcitonin-Gene-Related-Peptids blockiert und zur akuten Behandlung von Migräne mit oder ohne Aura bei Erwachsenen eingesetzt wird.",
        "en": "Ubrelvy is a drug that blocks calcitonin gene-related peptide receptors, used for acute treatment of migraine with or without aura in adults.",
        "quote": "Ubrelvy (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults."
      },
      {
        "de": "Juvederm Collection ist eine Reihe von Hautfüllern auf Hyaluronsäurebasis, die Volumen aufbauen oder Volumenverlust behandeln sollen, etwa an Wangen, Kinn, Lippen und unterem Gesicht.",
        "en": "Juvederm Collection is a range of dermal fillers made from hyaluronic acid, used to add volume or treat volume loss in areas such as the cheeks, chin, lips and lower face.",
        "quote": "Juvederm Collection is a portfolio of hyaluronic acid-based dermal fillers with a variety of approved indications in the U.S. and in other major markets around the world to augment or treat volume loss in the temples, undereye, cheeks, chin, lips and lower face."
      },
      {
        "de": "AbbVie verkauft seine Produkte weltweit in der Regel direkt an Großhändler, Distributoren, staatliche Stellen, Gesundheitseinrichtungen, Spezialapotheken und unabhängige Einzelhändler.",
        "en": "AbbVie generally sells its products worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.",
        "quote": "AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers"
      },
      {
        "de": "Bestimmte Produkte, darunter ästhetische Produkte und Geräte, werden ebenfalls direkt an Ärzte und andere zugelassene Gesundheitsdienstleister verkauft.",
        "en": "Certain products, including aesthetic products and devices, are also sold directly to doctors and other licensed health care providers.",
        "quote": "Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers."
      }
    ],
    "customers": [
      {
        "de": "Managed-Care-Anbieter wie Health Maintenance Organizations und Pharmacy Benefit Manager, Krankenhäuser und staatliche Behörden sind ebenfalls wichtige Kunden.",
        "en": "Managed care providers, such as health maintenance organizations and pharmacy benefit managers, hospitals and government agencies are also important customers.",
        "quote": "Managed care providers (for example, health maintenance organizations and pharmacy benefit managers), hospitals and state and federal government agencies"
      },
      {
        "de": "Außerhalb der Vereinigten Staaten verkauft AbbVie Produkte vor allem an Großhändler oder über Distributoren.",
        "en": "Outside the United States, AbbVie mainly sells products to wholesalers or through distributors.",
        "quote": "Outside the United States, AbbVie sells products primarily to wholesalers or through distributors"
      }
    ],
    "competition": [
      {
        "de": "AbbVies Immunologie-Produkte konkurrieren mit IL-23-Hemmern, IL-17-Hemmern, JAK-Hemmern, Biosimilars und anderen Produkten, die eine Reihe von Krankheitsbildern behandeln sollen.",
        "en": "AbbVie's immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars and other products intended to treat a number of disease states.",
        "quote": "AbbVie's immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars and other competitive products intended to treat a number of disease states"
      },
      {
        "de": "Auch der Preis ist ein Wettbewerbsfaktor.",
        "en": "Price is also a factor in competition.",
        "quote": "Price is also a competitive factor."
      },
      {
        "de": "Die Suche nach technologischen Innovationen bei Arzneimitteln ist ein bedeutender Aspekt des Wettbewerbs.",
        "en": "The search for technological innovation in pharmaceutical products is a significant part of competition.",
        "quote": "The search for technological innovations in pharmaceutical products is a significant aspect of competition."
      }
    ],
    "risks": [
      {
        "de": "Skyrizi und Rinvoq machten jeweils mehr als 10 % der gesamten Nettoerlöse aus, zusammen entfielen ungefähr 42 % der gesamten Nettoerlöse auf sie im Jahr 2025.",
        "en": "Skyrizi and Rinvoq each made up more than 10% of total net revenues, and together they accounted for approximately 42% of total net revenues in 2025.",
        "quote": "Skyrizi and Rinvoq each represented greater than 10% of AbbVie's total net revenues and, in aggregate, these products accounted for approximately 42% of total net revenues in 2025."
      },
      {
        "de": "Humira steht weltweit im direkten Wettbewerb mit Biosimilars.",
        "en": "Humira faces direct competition from biosimilars worldwide.",
        "quote": "Humira faces direct biosimilar competition globally"
      },
      {
        "de": "Die US-Stoffpatente auf Risankizumab und Upadacitinib, die den Wirkstoff selbst schützen, werden voraussichtlich 2033 auslaufen.",
        "en": "The US patents on the substances risankizumab and upadacitinib, which protect the chemical itself, are expected to expire in 2033.",
        "quote": "The United States composition of matter patents covering risankizumab and upadacitinib are expected to expire in 2033."
      },
      {
        "de": "Im August 2023 wählte das US-Gesundheitsministerium über CMS Imbruvica als eines von 10 Arzneimitteln aus, die staatlich festgelegten Preisen unterliegen.",
        "en": "In August 2023, the US health department, through CMS, selected Imbruvica as one of 10 medicines subject to government-set prices.",
        "quote": "In August 2023, the U.S. Department of Health and Human Services (HHS), through CMS, selected Imbruvica as one of 10 medicines subject to government-set prices"
      },
      {
        "de": "AbbVie hält die Kosten einer Produkthaftpflichtversicherung für höher als den wahrscheinlichen Nutzen des verfügbaren Versicherungsschutzes, daher trägt das Unternehmen seine Produkthaftungsverluste selbst.",
        "en": "AbbVie judges that the cost of product liability insurance outweighs the likely benefits of the coverage available, so its product liability losses are self-insured.",
        "quote": "AbbVie evaluates its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, AbbVie's product liability losses are self-insured."
      }
    ]
  }
}